Researchers at Cardiff University that were in the midst of analyzing blood from a bank accidentally stumbled into an "entirely new type of T-cell", according to The Daily Wire. The new cell carries a "never before seen" type of receptor that acts like a grappling hook, latching on to most human cancers. 

Prior therapies, called CAR-T and TCR-T, which use immune cells to attach to HLA molecules on cancer cells' surface, are incapable of fighting solid tumors, the article notes. HLA molecules vary in people, but the new therapy instead attaches to a molecule called MR1, which does not vary in humans. This gives the therapy a chance of fighting most cancers.

It also means people could share the treatment, which could allow banks of cells to be stored and offered quickly, as needed. 

The treatment has already worked on lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells. The study stated:

Human leukocyte antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor recognized and killed most human cancer types via the monomorphic MHC class-I related protein, MR1, while remaining inert to noncancerous cells … These finding offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.